discovering new anti-infectives
through deep phenotypic insights and machine learning
The "silent pandemic" is no longer silent.
Antimicrobial resistance (AMR) leading to drug-resistant infections is now a recognized and growing global health crisis. The limited pipeline of new drugs to treat the increase in drug resistant infections is a significant global concern.
Discovering new classes of anti-infectives to overcome drug resistant infections.
Our machine learning (ML)-based imaging platform for anti-infective drug discovery enables rapid and highly efficient identification of compounds with new and unexploited mechanisms of action at the very outset of the discovery process.
Our combined expertise, cutting edge technologies and novel workflows enable a rapid and early understanding of a compound’s mechanism of action, the potential addressable target product profile, and clinical utility based on deep analysis of cell behavior.Explore Platform
Delivering new classes of anti-infectives.
ArrePath is applying its technology platform to develop a pipeline of new classes of antibiotics,
targeting unexploited and under-exploited mechanisms of action, to address unmet clinical need and overcome drug resistance.
Recent News and Updates
We look forward to the World AMR Conference September 7-8 in Philadelphia, where our CEO, Lloyd Payne will be attending.07-19-2023
2023 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
ArrePath will be attending the 2023 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance happening on Sept. 19-22, 2023 in Boston, Mass. where you’ll hear the latest updates in drug development and antimicrobial resistance.07-14-2023
ArrePath will be attending the 7th AMR Conference, March 16-17, Basel, Switzerland, where our CEO, Lloyd Payne and founder Zemer Gitai will be attending.02-27-2023